Adderall XR Cost in New Jersey 2026

Adderall XR contains extended-release mixed amphetamine salts and functions as a Schedule II central nervous system stimulant. The FDA has approved it to treat ADHD in children age 6 and above, as well as narcolepsy. Shire originally created the Adderall XR brand, which Takeda acquired and currently owns. Multiple manufacturers produce generic versions of extended-release mixed amphetamine salts, including Teva. This article distinguishes between information that remains consistent for New Jersey patients and details that fluctuate regularly, such as insurance formulary placement, out-of-pocket costs, and individual copayment amounts, which should be verified when you fill your prescription.

Direct answer: No single "New Jersey price" for Adderall XR exists. What a patient pays depends on which of four pathways applies to them, commercial insurance formulary tier, NJ Medicaid (NJ FamilyCare) with prior authorization, cash-pay with a discount card, or a compounded preparation from a licensed 503A pharmacy, and each of those pathways is governed by rules or prices that change over time and are not fixed by federal law. Federal facts (schedule status, FDA-approved indications, refill restrictions) are stable. Dollar figures, specific copay tiers, and program eligibility are not, and this article does not present a manufacturer's list price or a specific cash-pay average as current because that number cannot be verified as accurate for 2026 from the sources available here.

What is actually stable versus what changes

Some facts about Adderall XR access in New Jersey are set by federal law or FDA labeling and do not vary by pharmacy or insurer:

• Mixed amphetamine salts XR is a DEA Schedule II controlled substance, per the FDA prescribing information.
• Schedule II prescriptions have zero refills; a new prescription is required for each fill. This is a federal DEA rule, not New Jersey-specific.
• FDA-approved indications are ADHD (ages 6 and up) and narcolepsy, per the same label.
• Generic mixed amphetamine salts XR is FDA-approved as bioequivalent to the branded product.
• Compounded preparations from 503A pharmacies are not FDA-approved products, consistent with the general regulatory framework for pharmacy compounding.

Everything downstream of those facts, what a specific pharmacy charges, what a specific insurer's tier copay is, what NJ Medicaid's current prior authorization criteria require, and whether a shortage is active, changes month to month and needs to be confirmed directly rather than taken from a general guide.

How NJ Medicaid handles Adderall XR

NJ FamilyCare (New Jersey Medicaid) generally requires prior authorization for stimulant medications, consistent with how most state Medicaid programs manage Schedule II ADHD medications. A documented ADHD diagnosis and a completed clinical evaluation are the baseline requirements a prescriber typically has to demonstrate. Beyond that general structure, this article does not state specific processing timelines, exact copay amounts, or specific documentation checklists as current fact, because NJ Medicaid's PA criteria and enrollee cost-sharing are set by the state program and can change. Patients and prescribers should confirm current requirements directly with NJ FamilyCare or the plan's pharmacy benefit manager before assuming a copay amount or approval timeline.

The scale of the underlying clinical need is documented by the National Institute of Mental Health, which discusses ADHD prevalence and diagnosis in children and adults; consult that source directly for current prevalence figures rather than relying on a number repeated secondhand.

Is compounded mixed amphetamine salts legal in New Jersey?

Yes, under defined conditions. A licensed 503A compounding pharmacy may prepare a patient-specific compounded version of mixed amphetamine salts when a valid, individually written prescription exists and there is a legitimate medical need, such as a dose form not commercially available. This is established by Section 503A of the Federal Food, Drug, and Cosmetic Act.

Two constraints matter clinically. First, the compounding pharmacy must hold both a New Jersey Board of Pharmacy license and a DEA Schedule II registration; a prescriber or patient should verify this directly with the pharmacy rather than assume it. Second, compounded preparations are not subject to FDA bioequivalence testing, so a compounded product may not behave identically to a manufactured generic in absorption or release profile. Switching between a manufactured generic and a compounded formulation is reasonably treated as a dose change requiring clinical follow-up, not a like-for-like substitution.

During the amphetamine shortage period that began in 2022, mixed amphetamine salts were widely reported as an affected product, and some patients nationally used 503A compounding as a continuity-of-care option during stockouts. Whether a shortage is currently active, and whether a given New Jersey compounder has capacity, both need to be checked at the time of need, this changes without notice.

Insurance coverage in New Jersey: what parity law requires and what it doesn't guarantee

The federal Mental Health Parity and Addiction Equity Act, together with Affordable Care Act requirements applying to non-grandfathered individual and small-group plans, generally requires that mental health and substance use benefits, including ADHD medication coverage for a covered diagnosis, not carry more restrictive cost-sharing or treatment limits than comparable medical benefits. That is a structural, federal-level protection. It does not mean every plan covers Adderall XR at the same tier, at the same copay, or without a step-therapy or prior authorization requirement, commercial formularies (Horizon BCBSNJ, Aetna, Cigna, UnitedHealthcare, and others operating in New Jersey) set their own tier placement and PA rules, and those change with each plan year.

Patients who believe an insurer is applying cost-sharing or limits inconsistent with parity requirements can file a complaint with the New Jersey Department of Banking and Insurance. Specific copay dollar amounts by tier are not stated here because they are plan-specific and change annually; check your plan's current formulary document rather than a generic figure.

Cash-pay and discount options

For patients without coverage, or for whom a discount price beats their insurance copay, several tools exist. None of the specific dollar prices below should be taken as current without checking at the point of purchase, since retail and discount pricing shifts by pharmacy, region, and time:

• Discount cards (GoodRx and similar prescription discount platforms) negotiate pharmacy pricing independent of insurance and cannot be combined with insurance at checkout.
• Manufacturer or authorized-generic patient assistance programs may exist for uninsured, low-income patients; eligibility and availability change annually and should be checked through NeedyMeds directly.
• 340B pricing is available only through care received at a participating Federally Qualified Health Center or other 340B-covered entity, not at a retail pharmacy independent of that care relationship.
• New Jersey PAAD (Pharmaceutical Assistance to the Aged and Disabled) may assist eligible residents 65 and older, or those with a qualifying disability, who meet income thresholds; program rules are administered by the state and should be confirmed with the NJ Division of Aging Services rather than assumed from a secondary source.

Telehealth prescribing of a Schedule II stimulant in New Jersey

New Jersey permits telehealth evaluation and prescribing for ADHD, including Schedule II stimulants, but this rests on a shifting federal framework. The Ryan Haight Online Pharmacy Consumer Protection Act of 2008 originally required an in-person evaluation before any controlled substance could be prescribed by telemedicine. DEA-issued telemedicine exceptions adopted since the COVID-19 public health emergency have allowed audio-video prescribing without a prior in-person visit under specific conditions, and the DEA has repeatedly extended and revised these exceptions. Because this is an actively evolving regulatory area, the current rule in effect for 2026 needs to be confirmed against the DEA's own published notices rather than assumed stable from a prior year's guidance.

Whatever the current federal exception, a New Jersey-licensed prescriber conducting a telehealth ADHD evaluation still needs a valid New Jersey medical license and DEA Schedule II registration, and must query the New Jersey Prescription Monitoring Program before issuing each Schedule II prescription. The New Jersey Division of Consumer Affairs maintains current telehealth prescribing rules for licensed practitioners in the state.

Pharmacy dispensing rules that affect access, not price

New Jersey pharmacies dispensing Adderall XR follow federal Schedule II rules: no refills, a new written or electronic prescription for each 30-day supply, and no mail-order 90-day fills of the kind allowed for non-controlled medications. Quantity limits and any additional state-level dispensing restrictions should be confirmed with the pharmacy or the New Jersey Board of Pharmacy, since state-level detail can change independently of federal rule.

Supply shortages and what to do if a pharmacy is out of stock

Mixed amphetamine salts have been reported among frequently affected medications at various points since 2022, with fluctuating recovery. Whether a shortage is active in New Jersey right now, and which strengths are affected, needs to be checked against the current FDA shortage database rather than assumed from a prior year's pattern. If a pharmacy cannot fill a prescription, reasonable options include checking other pharmacies, asking a prescriber whether a licensed 503A compounding pharmacy can prepare a patient-specific alternative, or discussing a therapeutic substitution such as lisdexamfetamine or an extended-release methylphenidate. Dose conversion between stimulant classes is not a simple milligram-for-milligram exercise and should be made by the prescriber, not the patient.

What the clinical evidence actually supports

The scale of ADHD as a condition, and the general effectiveness of stimulant treatment, rest on evidence that predates and is independent of the cost questions above.

The Multimodal Treatment Study of ADHD (MTA), a large randomized trial in children with ADHD published in 1999, found that carefully managed stimulant medication produced greater reductions in core ADHD symptoms over 14 months than intensive behavioral treatment alone or routine community care, with the best overall outcomes in the group receiving combined medication and behavioral treatment [1]. This trial remains a frequently cited anchor for stimulant-first treatment approaches in children, though it is now more than two decades old and treatment patterns have evolved since.

Guideline literature discussing pediatric ADHD diagnosis and treatment history, including work published in Pediatrics, describes stimulant medication as a recommended first-line pharmacologic option for children 6 and older with a confirmed ADHD diagnosis [2]. Readers relying on a specific current guideline recommendation should consult the American Academy of Pediatrics' most recent clinical practice guideline directly rather than a secondary description, since guideline wording can be more precise or more conditional than a paraphrase conveys.

A systematic review and network meta-analysis published in Lancet Psychiatry compared multiple ADHD medications across children, adolescents, and adults, and found amphetamine-class stimulants among the medications with the strongest evidence for symptom reduction relative to other drug classes in the analysis [3]. The exact effect-size figures for specific age subgroups vary within that paper and should be pulled from the full text rather than quoted as a single number, since this summary does not have independent confirmation of a specific point estimate for adults.

Known adverse effects relevant to a prescribing decision include appetite suppression, insomnia, and increases in blood pressure and heart rate. The FDA label carries a boxed warning about abuse and dependence potential, which is the regulatory basis for Schedule II status [4].

Evidence boundary: It is established that stimulant medication, including mixed amphetamine salts, reduces core ADHD symptoms in both children and adults across multiple trials and meta-analyses. It is established that compounded preparations are not FDA-approved and may not be bioequivalent to manufactured products. It is not established, from the sources available here, what a specific 2026 cash price, insurer copay, or NJ Medicaid processing timeline is, those require direct verification with the payer, pharmacy, or state program at the time a patient needs the information.

Verification checklist before you rely on a price or coverage answer

Use this to separate what you can trust from a general reference source versus what only your pharmacy, insurer, or the state program can confirm right now.

Stable facts you can treat as settled (federal law, FDA labeling):

• Mixed amphetamine salts XR is Schedule II; no refills are permitted; a new prescription is required for each fill.
• FDA-approved uses are ADHD (6+) and narcolepsy.
• Generic mixed amphetamine salts XR is FDA-rated bioequivalent to brand Adderall XR.
• Compounded preparations from a 503A pharmacy are not FDA-approved products.

Facts that change and must be re-verified at the time of your fill:

• Your specific insurer's current formulary tier and copay for generic mixed amphetamine salts XR (call member services or check the current plan formulary document, not last year's).
• NJ FamilyCare's current prior authorization criteria and documentation requirements for stimulants (confirm with the plan's pharmacy benefit manager).
• Whether a discount card price beats your insurance copay this month, at this specific pharmacy.
• Whether the manufacturer or authorized-generic patient assistance program you're considering is currently accepting applications and what its income cutoff is (check NeedyMeds or the manufacturer directly).
• Whether the 503A compounding pharmacy you're considering currently holds an active New Jersey Board of Pharmacy license and DEA Schedule II registration.
• Whether an active FDA shortage listing currently affects your strength or formulation.
• Current DEA telemedicine prescribing rules for Schedule II substances, since these have changed on a rolling basis since 2020.

If you cannot check an item on the second list yourself, ask your prescriber's office or the pharmacy directly before assuming a price or approval outcome.

When to seek urgent care instead of troubleshooting cost

Cost and access barriers are not a reason to abruptly stop a stimulant medication without medical guidance, particularly at higher doses, since abrupt discontinuation can cause rebound symptoms. Seek urgent medical attention for chest pain, fainting, signs of an allergic reaction, or significant mood or behavioral changes after starting or changing a stimulant dose, rather than waiting for a scheduled follow-up.